Genscript Biotech's (HKG:1548) associate Legend Biotech will present preliminary clinical data for LB2501 at a late-breaking session at the European Hematology Association 2026 Congress, according to a Tuesday Hong Kong bourse filing.
Shares of the cancer drug company were up nearly 11% in Wednesday afternoon trading.
The data is for the drug being tested in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
The conference will take place from June 11 to 14 in Stockholm, Sweden.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.